PDGene

Gene overview of all published PD-association studies for HLA-DRA

Gene:

HLA-DRA (DASS-397D15.1; FLJ51114; HLA-DRA1; MLRW; PARK18)

View on MSGene

Protein:

major histocompatibility complex, class II, DR alpha (HLA class II histocompatibility antigen, DR alpha chain; MHC cell surface glycoprotein; MHC class II antigen DRA; histocompatibility antigen HLA-DR alpha)

Chromosome:

6 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 2 October 2011

1. Case-Control Studies (by ethnic group)
				PD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
Edwards, 2010	Overlaps with Hamza, 2010 (HIHG-GWAS)	CL	1 (detail)	604 (37%)	C	56.3 + 12.9 (-)	64.5 + 12.1 (-)	619 (66%)	69.3 + 9.8 (-)	n.a.
Fung, 2006	Overlaps with Simon-Sanchez, 2009 (USA)	CL	1 (detail)	267 (-)	C	-	-	270 (-)	68 (55-88)	n.a.
Hamza, 2010	USA (NGRC-GWAS)	CL	1 (detail)	2000 (33%)	C	58.3 + 11.9 (-)	67.2 + 10.6 (-)	1986 (61%)	70.3 + 14 (21-90)	Positive
Hamza, 2010	USA (HIHG-GWAS-Edwards)	CL	1 (detail)	604 (-)	C	-	-	612 (-)	-	Positive
Hamza, 2010	Overlaps with Pankratz, 2008 (CIDR-GWAS)	CL	1 (detail)	843 (-)	C	-	-	856 (-)	-	n.a.
Mata, 2011	Spain	CL	1 (detail)	1445 (44%)	C	60 + 12.2 (-)	68.1 + 11.2 (-)	1161 (58%)	68.9 + 11.2 (-)	Negative
Pankratz, 2008	USA (PROGENI, GenePD)	CL	2 (detail)	857 (41%)	C	61.9 + 10.8 (-)	-	867 (60%)	54.8 + 13.1 (-)	Negative
Puschmann, 2011	Ireland	CL	1 (detail)	354 (44%)	C	52 + 10 (18-77)	68 + 10 (38-94)	360 (64%)	73 + 22 (24-104)	Positive
Puschmann, 2011	Poland	CL	1 (detail)	343 (38%)	C	56 + 12 (23-81)	69 + 11 (40-93)	312 (48%)	65 + 16 (24-99)	Positive
Puschmann, 2011	USA	CL	1 (detail)	616 (37%)	C	63 + 12 (25-94)	72 + 11 (31-99)	633 (58%)	70 + 13 (21-94)	Negative
Simon-Sanchez, 2009	USA, Germany (GWAS)	CL,PO	1 (detail)	1745 (45%)	C	55.8 (7-98)	-	4047 (50%)	-	Negative
Simon-Sanchez, 2009	USA (NINDS-GWAS)	CL	1 (detail)	931 (40%)	C	-	-	790 (58%)	-	Negative
Simon-Sanchez, 2011	Netherlands (GWAS)	CL,PO	2 (detail)	772 (36%)	U	55.3 (16-84)	62.3 (29-89)	2024 (56%)	53.7 (45-95)	Negative
Asian
Guo, 2011	China	CL	1 (detail)	284 (38%)	C	62.2 + 5.8 (-)	66.2 + 8.4 (-)	258 (38%)	66.3 + 8.5 (-)	Positive

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis -> "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.